// App-Quantinova.ai

: Synergistic Dual Inhibition of BCR-ABL1 and the Unfolded Protein Response Causes p38 MAPK-Mediated Cell Death and Sensitizes BCR-ABL1+ Acute Lymphoblastic Leukemia to Dexamethasone

Researchers

Presenter

  • Margherita Vieri

Principal Investigators

  • Christian Preisinger

  • Mirle Schemionek

  • Azam Salimi

  • John B. Patterson

  • Afshin Samali

  • Tim H Brmmendorf

  • Iris Appelmann

  • Behzad Kharabi Masouleh

Medical Centers

  • Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, RWTH Aachen University Hospital, Aachen, Germany

  • Proteomics Facility, Interdisciplinary Centre for Clinical Research (IZKF), Faculty of Medicine, RWTH Aachen University, Aachen, Germany

  • MannKind Corporation, Valencia, CA

  • Department of Microbiology, National University of Ireland, Galway, Ireland

  • Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, RWTH Aachen University Hospital, Aachen, Germany

Locations

  • Germany

  • United States

  • Ireland

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Nucleoside diphosphate kinase A

  • Heat shock protein 27

Drug/Treatment

  • Afimoxifene

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Nilotinib

  • Doramapimod

  • Trypsin

  • DMSO

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved